Efficacy of Single‐Agent Chemotherapy for Patients with Advanced Invasive Lobular Carcinoma: A Pooled Analysis from Three Clinical Trials

Conclusion.This retrospective analysis suggests that eribulin demonstrates similar efficacy in patients with ILC and IDC with metastatic disease who have previously received an anthracycline and a taxane.Implications for Practice.Data on the efficacy of chemotherapy regimens in patients with advanced invasive lobular carcinoma (ILC) of the breast are limited. This pooled retrospective analysis of three clinical studies demonstrates that the magnitude of benefit of eribulin in the metastatic setting did not differ between patients with ILC versus invasive ductal carcinoma (IDC), even when restricting for patients with estrogen receptor‐positive/HER2‐negative IDC.
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Breast Cancer Source Type: research

Related Links:

Background: Infiltrating lobular carcinoma (ILC) is the second most common histologicaI subtype of breast cancer, accounting for 10% of all cases. ILC has a characteristic genomic profile. ILC shows a high frequency of cadherin 1 (CDH1) mutations, along with loss of phosphatase and tensin homolog (PTEN), activation of alpha serine/threonine kinase (AKT), and mutations in T-box transcription factor (TBX3) and forkhead box protein A1 (FOXA1). We suspected that another gene, von Willebrand factor (VWF), might also be part of the profile, since coagulation tests reveal significant differences in patients with breast cancer. Ma...
Source: Cancer Genomics and Proteomics - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
CONCLUSION: This retrospective analysis suggests that eribulin demonstrates similar efficacy in patients with ILC and IDC with metastatic disease who have previously received an anthracycline and a taxane. IMPLICATIONS FOR PRACTICE: Data on the efficacy of chemotherapy regimens in patients with advanced invasive lobular carcinoma (ILC) of the breast are limited. This pooled retrospective analysis of three clinical studies demonstrates that the magnitude of benefit of eribulin in the metastatic setting did not differ between patients with ILC versus invasive ductal carcinoma (IDC), even when restricting for patients wi...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
Authors: Heng C, Wei T, Yingbing T, Hanzhong L Abstract Two middle-aged females presented with a mass located in the lateral quadrant of the breast. Both patients received modified radical surgery for breast cancer, radiotherapy, and chemotherapy and have been living without evidence of disease for more than one year. Under the microscope, we observed that the tumour cells were organised in a solid nest-like or leafy distribution and comprised sebaceous gland cells and oval or fusiform cells. The differences between the two cases are as follows: First, the mass in the first case had a mixed echo pattern on ultrasou...
Source: Polish Journal of Pathology - Category: Pathology Tags: Pol J Pathol Source Type: research
This study seeks to evaluate national trends in the use of NCT for ILC compared with IDC, and determine if there is a subset of ILC patients who demonstrate favorable response rates.
Source: Journal of Surgical Research - Category: Surgery Authors: Source Type: research
Conclusions: Oncoplastic breast reductions allow wide resections with free margins and can be used for large cancers as an alternative to mastectomy.
Source: Annals of Surgery - Category: Surgery Tags: Original Articles Source Type: research
Conclusions: Based on comprehensive analysis of haemostatic profile depending on clinicopathological features we suggest that haemostatic parameters play crucial roles in invasion and metastases of malignant tumours. PMID: 29475895 [PubMed - as supplied by publisher]
Source: Bioscience Reports - Category: Biomedical Science Authors: Tags: Biosci Rep Source Type: research
CONCLUSIONS: In females with breast cancer, a possible metastasis in the stomach should be taken into account. Maspin and VSIG1 are not involved in breast cancer histogenesis. The Wnt/β-catenin signaling is not involved in the lobular carcinoma progression. The CD44/HER2 positivity in ductal carcinoma cells might indicate high risk of distant metastasis and low response to chemotherapy. PMID: 29090670 [PubMed - as supplied by publisher]
Source: Recent Patents on Anti-Cancer Drug Discovery - Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research
ConclusionFor patients with ER-positive ILC, 8% were in the high-risk and 72% were in the intermediate-risk groups as per the TAILORx RS cutoffs. In the high-risk group, the RS predicted a lower 5-year BCSS. Adjuvant chemotherapy did not seem to confer a survival benefit for either the intermediate- or the high-risk cohorts.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
AbstractBackgroundThe benefit of neoadjuvant chemotherapy (NAC) in patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2 −) breast cancers and in invasive lobular carcinoma (ILC) is uncertain due to the low rates of pathologic complete response (pCR).ObjectiveThe aim of this study was to determine if pathologic features can identify subsets likely to benefit from NAC.MethodsPatients with stage I –III ER+, HER2− breast cancer receiving NAC were retrospectively reviewed. Endpoints were downstaging to breast-conserving surgery (BCS) and nodal pCR after NAC. Pa...
Source: Annals of Surgical Oncology - Category: Cancer & Oncology Source Type: research
Abstract BACKGROUND: The benefit of neoadjuvant chemotherapy (NAC) in patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancers and in invasive lobular carcinoma (ILC) is uncertain due to the low rates of pathologic complete response (pCR). OBJECTIVE: The aim of this study was to determine if pathologic features can identify subsets likely to benefit from NAC. METHODS: Patients with stage I-III ER+, HER2- breast cancer receiving NAC were retrospectively reviewed. Endpoints were downstaging to breast-conserving surgery (BCS) and nodal pCR after...
Source: Ann Oncol - Category: Cancer & Oncology Authors: Tags: Ann Surg Oncol Source Type: research
More News: Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Clinical Trials | Ductal Carcinoma | Lobular Carcinoma | Study